Switch theme
Sign up to access all valuation multiples
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
1998
900
LTM Revenue $977M
LTM EBITDA $179M
$813M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Emergent BioSolutions has a last 12-month revenue of $977M and a last 12-month EBITDA of $179M.
In the most recent fiscal year, Emergent BioSolutions achieved revenue of $1.0B and an EBITDA of $36.9M.
Emergent BioSolutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Emergent BioSolutions valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B | XXX | XXX | XXX |
| Gross Profit | $386M | $318M | XXX | XXX | XXX |
| Gross Margin | 38% | 31% | XXX | XXX | XXX |
| EBITDA | -$518M | $36.9M | XXX | XXX | XXX |
| EBITDA Margin | -51% | 4% | XXX | XXX | XXX |
| Net Profit | -$224M | -$761M | XXX | XXX | XXX |
| Net Margin | -22% | -75% | XXX | XXX | XXX |
| Net Debt | $763M | $749M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Emergent BioSolutions's stock price is $5.
Emergent BioSolutions has current market cap of $249M, and EV of $813M.
See Emergent BioSolutions trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $813M | $249M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Emergent BioSolutions has market cap of $249M and EV of $813M.
Emergent BioSolutions's trades at 0.8x LTM EV/Revenue multiple, and 4.5x LTM EBITDA.
Analysts estimate Emergent BioSolutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Emergent BioSolutions and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $813M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 22.0x | XXX | XXX | XXX |
| P/E | -1.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 22.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEmergent BioSolutions's NTM/LTM revenue growth is -11%
Emergent BioSolutions's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Emergent BioSolutions's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Emergent BioSolutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Emergent BioSolutions and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -107% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -8% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emergent BioSolutions acquired XXX companies to date.
Last acquisition by Emergent BioSolutions was XXXXXXXX, XXXXX XXXXX XXXXXX . Emergent BioSolutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Emergent BioSolutions founded? | Emergent BioSolutions was founded in 1998. |
| Where is Emergent BioSolutions headquartered? | Emergent BioSolutions is headquartered in United States of America. |
| How many employees does Emergent BioSolutions have? | As of today, Emergent BioSolutions has 900 employees. |
| Who is the CEO of Emergent BioSolutions? | Emergent BioSolutions's CEO is Mr. Joseph C. Papa. |
| Is Emergent BioSolutions publicy listed? | Yes, Emergent BioSolutions is a public company listed on NYS. |
| What is the stock symbol of Emergent BioSolutions? | Emergent BioSolutions trades under EBS ticker. |
| When did Emergent BioSolutions go public? | Emergent BioSolutions went public in 2006. |
| Who are competitors of Emergent BioSolutions? | Similar companies to Emergent BioSolutions include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Emergent BioSolutions? | Emergent BioSolutions's current market cap is $249M |
| What is the current revenue of Emergent BioSolutions? | Emergent BioSolutions's last 12-month revenue is $977M. |
| What is the current EBITDA of Emergent BioSolutions? | Emergent BioSolutions's last 12-month EBITDA is $179M. |
| What is the current EV/Revenue multiple of Emergent BioSolutions? | Current revenue multiple of Emergent BioSolutions is 0.8x. |
| What is the current EV/EBITDA multiple of Emergent BioSolutions? | Current EBITDA multiple of Emergent BioSolutions is 4.5x. |
| What is the current revenue growth of Emergent BioSolutions? | Emergent BioSolutions revenue growth between 2023 and 2024 was -1%. |
| Is Emergent BioSolutions profitable? | Yes, Emergent BioSolutions is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
